NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Elutia Inc. (ELUT) Stock Analysis

Elutia Inc. (ELUT) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

ELUT

$0.82

−$0.02 (−2.26%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ELUT with… →

ELUT Key Statistics

As of Sep 4, 2026
Trading
Open
$0.85
Previous Close
$0.84
Day's Range
0.82–0.89
52-Week Range
0.50–2.04
Volume
38.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.88
Valuation
Market Cap
$36.37M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.00
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.62
Financials (FY)
Revenue (FY)
$12.29M−15.03%
Net Income (FY)
$53.38M
Profit marginThe share of revenue left as profit after all costs and taxes.
426.90%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
44.29M
1-Year Return
−59.15%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
76.36K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ELUT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+18.47%
2025−81.47%
2024+73.15%
2023−49.18%
2022−32.54%
2021−53.78%
2020 (partial year)−6.00%

As of September 4, 2026.

ELUT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$12.29M$53.38M434.2%
2024$14.47M−$53.95M−372.9%
2023$24.75M−$37.66M−152.2%
2022$23.85M−$32.90M−137.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$12.29M$6.60M−$18.41M$53.38M434.2%
2024$14.47M$6.72M−$19.34M−$53.95M−372.9%
2023$24.75M$11.05M−$20.54M−$37.66M−152.2%
2022$23.85M$11.64M−$29.99M−$32.90M−137.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ELUT Valuation vs Medical Devices Median

Median of 151 stocks
MetricELUTMedical Devices medianvs median
P/S ratio3.002.981% above
Profit margin426.90%−1.69%428.6 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Elutia Inc. (ELUT) is capitalised at $36.37M on the latest close. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 25.

The most recent close on file for ELUT is $0.82, dated September 4, 2026. That is −$0.02 (−2.26%) against the previous close. The 52-week range on file runs from $0.50 to $2.04. The latest close sits 64.2% above that 52-week low.

Financial Health

In fiscal 2025, Elutia Inc. reported revenue of $12.29M. Against the prior fiscal year total of $14.47M, that is a change of −15.03%. Net income for the same year was $53.38M. Profit margin runs at 426.9%. That is 428.6 percentage points above the Medical Devices median of −1.69%. Trailing earnings per share are −0.62.

Across the 4 fiscal years on file, revenue moves from $23.85M in 2022 to $12.29M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 3 times revenue. On price-to-sales that is 0.7% above the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −59.15%. Measured over 5 years, that is −37.19% a year compounded. The reported beta is 0.88. Daily returns over the trailing 5 years annualize to a volatility of 92.81%.

Growth & Income

The record shows no dividend for ELUT.

So far in 2026 the price is +18.47%. Across the complete calendar years on file, 2024 returned +73.15% and 2025 returned −81.47%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Elutia Inc. (ELUT) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Elutia Inc. ELUT $36.37M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Elutia Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Elutia Inc.

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

Visit website →